Key Points
- Mineralys Therapeutics insider David Malcom Rodman sold 417 shares on May 18 at an average price of $27.55, totaling $11,488.35. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Rodman has also been actively selling shares in recent weeks, including several much larger transactions in May and April. After the latest sale, he still owned 63,443 shares valued at about $1.75 million.
- Mineralys shares closed at $26.03, below the 50-day average but above the 1-year low, while analysts remain broadly positive overall. The stock has a Moderate Buy consensus rating with an average price target of $49.33.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 417 shares of the company's stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $27.55, for a total transaction of $11,488.35. Following the completion of the transaction, the insider directly owned 63,443 shares in the company, valued at $1,747,854.65. The trade was a 0.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Malcom Rodman also recently made the following trade(s):
- On Tuesday, May 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $29.36, for a total value of $186,377.28.
- On Wednesday, May 13th, David Malcom Rodman sold 14,056 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.58, for a total value of $401,720.48.
- On Monday, May 11th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $29.71, for a total value of $64,500.41.
- On Friday, April 17th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $31.33, for a total value of $13,033.28.
- On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total value of $175,585.68.
- On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.54, for a total value of $373,099.32.
- On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total transaction of $59,414.60.
- On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total transaction of $173,744.76.
- On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total value of $369,163.08.
- On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total value of $58,269.64.
Mineralys Therapeutics Price Performance
Shares of NASDAQ MLYS opened at $26.03 on Wednesday. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -12.70 and a beta of 0.49. The stock's 50-day moving average is $27.05 and its two-hundred day moving average is $32.37. Mineralys Therapeutics, Inc. has a 1-year low of $12.59 and a 1-year high of $47.65.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.04. Equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.
Institutional Trading of Mineralys Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MLYS. Bank of America Corp DE lifted its position in shares of Mineralys Therapeutics by 11.5% during the 1st quarter. Bank of America Corp DE now owns 1,100,372 shares of the company's stock worth $29,809,000 after buying an additional 113,092 shares during the last quarter. Stempoint Capital LP raised its stake in Mineralys Therapeutics by 83.9% during the 1st quarter. Stempoint Capital LP now owns 533,378 shares of the company's stock worth $14,449,000 after acquiring an additional 243,329 shares in the last quarter. ADAR1 Capital Management LLC raised its stake in Mineralys Therapeutics by 13.5% during the 1st quarter. ADAR1 Capital Management LLC now owns 154,686 shares of the company's stock worth $4,190,000 after acquiring an additional 18,455 shares in the last quarter. California State Teachers Retirement System lifted its position in Mineralys Therapeutics by 41.3% in the first quarter. California State Teachers Retirement System now owns 61,266 shares of the company's stock valued at $1,660,000 after acquiring an additional 17,918 shares during the last quarter. Finally, Rock Springs Capital Management LP lifted its position in Mineralys Therapeutics by 2.8% in the first quarter. Rock Springs Capital Management LP now owns 439,751 shares of the company's stock valued at $11,913,000 after acquiring an additional 12,155 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company's stock.
Analysts Set New Price Targets
Several research analysts have commented on MLYS shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a research report on Tuesday, March 10th. Wall Street Zen downgraded shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Jefferies Financial Group reissued a "hold" rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a report on Friday, March 13th. Finally, Bank of America lifted their price target on Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a "buy" rating in a report on Friday, March 13th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $49.33.
Check Out Our Latest Stock Analysis on Mineralys Therapeutics
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
